Back to top
more

Fulgent Genetics (FLGT)

(Real Time Quote from BATS)

$20.69 USD

20.69
105,562

-0.09 (-0.43%)

Updated Aug 6, 2025 12:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Fullgent Genetics (FLGT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Fullgent Genetics (FLGT) closed at $63.87, marking a +1.96% move from the previous day.

Nitish Marwah headshot

4 Stocks With High Net Income Ratio to Scoop Up

by Nitish Marwah

FLGT, AAWW, BBW, and QDEL passed the screen for the stocks with a high net income ratio.

Zacks Equity Research

New Strong Buy Stocks for January 26th

by Zacks Equity Research

FLGT, LPX, STC, GFED, and FBNC have been added to the Zacks Rank #1 (Strong Buy) List on January 26th.

Zacks Equity Research

Fullgent Genetics (FLGT) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Fullgent Genetics (FLGT) closed at $60.72 in the latest trading session, marking a +0.03% move from the prior day.

Zacks Equity Research

Fullgent Genetics (FLGT) Stock Moves -0.62%: What You Should Know

by Zacks Equity Research

Fullgent Genetics (FLGT) closed at $81.34 in the latest trading session, marking a -0.62% move from the prior day.

Zacks Equity Research

Fullgent Genetics (FLGT) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Fullgent Genetics (FLGT) closed at $81.25, marking a +1.4% move from the previous day.

Nitish Marwah headshot

4 Profitable Stocks to Boost Returns Using Net Income Ratio

by Nitish Marwah

FLGT, LGO, CTRN, and TGH have been selected as the top picks with a high net income ratio.

Sandip Chakraborty headshot

Buy These 3 Stocks With Momentum Anomaly for Higher Returns

by Sandip Chakraborty

Avis Budget Group (CAR), Signet Jewelers (SIG) and Fulgent Genetics (FLGT) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.

Zacks Equity Research

New Strong Buy Stocks for December 28th

by Zacks Equity Research

AAWW, BERY, CAL, FLGT, and MUSA have been added to the Zacks Rank #1 (Strong Buy) List on December 28th.

Zacks Equity Research

Best Momentum Stocks to Buy for December 28th

by Zacks Equity Research

MUSA, JOAN, FLGT, and AHH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 28, 2021.

Zacks Equity Research

Has Bio-Rad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.

Zacks Equity Research

Best Momentum Stocks to Buy for December 21st

by Zacks Equity Research

AMTB, BBW, FLGT, and BLDR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 21, 2021.

Zacks Equity Research

Fullgent Genetics (FLGT) Crossed Above the 50-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

Zacks Equity Research

Best Momentum Stocks to Buy for December 8th

by Zacks Equity Research

ACLS, FLGT, GHLD, and BERY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 8, 2021.

Zacks Equity Research

Is Bio-Rad Laboratories (BIO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.

Zacks Equity Research

New Strong Buy Stocks for December 8th

by Zacks Equity Research

ACLS, BERY, CTRN, FLGT, and GMS have been added to the Zacks Rank #1 (Strong Buy) List on December 8, 2021

Zacks Equity Research

New Strong Buy Stocks for December 2nd

by Zacks Equity Research

GOLF, FLGT, GNK, CDEV, and ATCO have been added to the Zacks Rank #1 (Strong Buy) List on December 2nd.

Zacks Equity Research

Is Bio-Rad Laboratories (BIO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for Fullgent Genetics (FLGT) Stock

by Zacks Equity Research

Fullgent Genetics (FLGT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Best Momentum Stocks to Buy for November 19th

by Zacks Equity Research

AOSL, FLGT, AMRC, and SAIA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 19, 2021.

Zacks Equity Research

New Strong Buy Stocks for November 19th

by Zacks Equity Research

AOSL, FLGT, LAZY, MATX, and SCHN have been added to the Zacks Rank #1 (Strong Buy) List on November 19, 2021.

Zacks Equity Research

Fullgent Genetics (FLGT) Crossed Above the 200-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?

Zacks Equity Research

New Strong Buy Stocks for November 11th

by Zacks Equity Research

BLDR, FLGT, MRBK, CC, and NMRK have been added to the Zacks Rank #1 (Strong Buy) List on November 11th.

Zacks Equity Research

Fullgent Genetics (FLGT) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Fullgent Genetics (FLGT) delivered earnings and revenue surprises of 202.31% and -13.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fulgent Genetics (FLGT) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

The recent buyout of CSI Laboratories and strategic investments in early cancer screening are likely to have contributed to growth for Fulgent Genetics (FLGT).